Amylyx Pharmaceuticals (AMLX) investor relations material

Key program updates and clinical development

• Lead asset avexitide is a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia (PBH), a severe condition affecting about 160,000 people in the U.S., with no approved treatments currently available.

• Five prior trials of avexitide showed substantial reductions in hypoglycemia, supporting FDA Breakthrough Therapy designation; phase III pivotal study is ongoing with top-line results expected in Q3, following completion of enrollment in March.

• The phase III trial uses a 90 mg dose for improved day and night coverage, with robust powering to detect a 35% relative difference in hypoglycemic events, based on strong phase II data.

• Clinical trial design emphasizes consistency with prior studies, rigorous patient selection, real-time monitoring, and adherence to FDA-reviewed protocols for event adjudication.

• NDA preparation and commercialization efforts are underway, targeting a 2027 launch, with cash runway into 2028 covering all pre-commercial and launch activities.

Market opportunity and commercialization strategy

• PBH prevalence is estimated at 160,000 in the U.S., with the population expected to grow as bariatric surgeries continue at over 200,000 annually.

• Patients are primarily managed by adult endocrinologists and specialty centers, with growing awareness due to new ICD-10 coding and inclusion in board exams.

• Current standard of care is strict diet management, with off-label medications offering limited efficacy; physicians express high interest in a targeted treatment.

• Commercial infrastructure will be sized for rare disease, leveraging digital tools and focusing initial efforts on high-volume specialty centers.

• Pricing strategy will reference recent rare endocrine drug launches with premium orphan pricing, aiming for strong payer coverage due to high unmet need.

Pipeline and innovation

• Intellectual property for avexitide extends to at least 2037, with potential for further extension; a long-acting GLP-1 receptor antagonist (AMX0318) is in IND-enabling studies, targeting once-weekly dosing and clinical entry next year.

• Collaboration with Gubra leverages advanced peptide discovery and AI-driven candidate selection for next-generation therapies.

• No significant competitors remain in PBH, with other programs discontinued or failing endpoints.

• ALS pipeline includes AMX0114, a calpain-2 antisense oligonucleotide in multiple ascending dose studies, with biomarker data to be presented soon.